These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 33734949)

  • 61. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.
    Thompson Coon J; Rogers G; Hewson P; Wright D; Anderson R; Cramp M; Jackson S; Ryder S; Price A; Stein K
    Health Technol Assess; 2007 Sep; 11(34):1-206. PubMed ID: 17767898
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cost-effectiveness and cost-utility analysis of OTC use of simvastatin 10 mg for the primary prevention of myocardial infarction in Iranian men.
    Amirsadri M; Hassani A
    Daru; 2015 Dec; 23():56. PubMed ID: 26717884
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cost-effectiveness of couple-based immunization strategy to prevent mother-to-child transmission of hepatitis B virus in China: A decision-analytic Markov model.
    Jing W; Liu J; Wu Y; Ma Q; Liu M
    EClinicalMedicine; 2020 Feb; 19():100264. PubMed ID: 32055793
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand.
    Blakely T; Kvizhinadze G; Karvonen T; Pearson AL; Smith M; Wilson N
    Vaccine; 2014 May; 32(22):2645-56. PubMed ID: 24662710
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Cost-utility analysis on universal childhood hepatitis A vaccination in regions with different anti-HAV prevalence rates of China].
    Pan XJ; Feng YM; Zhuang GH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2012 Aug; 33(8):862-6. PubMed ID: 22967346
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis.
    Wong WW; Hicks LK; Tu HA; Pritchard KI; Krahn MD; Feld JJ; Chan KK
    Breast Cancer Res Treat; 2015 Jun; 151(3):639-52. PubMed ID: 25962692
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Impact and Cost-Effectiveness of Biomedical Interventions on Adult Hepatitis B Elimination in China: A Mathematical Modelling Study.
    Wang X; Du Z; Wang Y; Wang J; Huang S; Wang Y; Gu J; Deng W; Gilmour S; Li J; Hao Y
    J Epidemiol Glob Health; 2023 Sep; 13(3):517-527. PubMed ID: 37349664
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Economic evaluation of varicella vaccination strategies in Jiangsu province, China: a decision-tree Markov model.
    Wang Q; Xiu S; Yang L; Huang J; Cui T; Shi N; Wang X; Shen Y; Chen E; Lu B; Jin H; Lin L
    Hum Vaccin Immunother; 2021 Nov; 17(11):4194-4202. PubMed ID: 34357833
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Cost-effectiveness of community-based treatment of chronic hepatitis B in China].
    Zhang SX; Yang PC; Cai YL; Lin Y; Zou YH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jul; 38(7):860-867. PubMed ID: 28738456
    [No Abstract]   [Full Text] [Related]  

  • 70. Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country.
    Suijkerbuijk AWM; van Hoek AJ; Koopsen J; de Man RA; Mangen MJ; de Melker HE; Polder JJ; de Wit GA; Veldhuijzen IK
    PLoS One; 2018; 13(11):e0207037. PubMed ID: 30408079
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Regional variation in the cost effectiveness of childhood hepatitis A immunization.
    Jacobs RJ; Greenberg DP; Koff RS; Saab S; Meyerhoff AS
    Pediatr Infect Dis J; 2003 Oct; 22(10):904-14. PubMed ID: 14551492
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.
    Saab S; Virabhak S; Parisé H; Johnson S; Wang A; Misurski D; Gonzalez YS; Juday T
    Adv Ther; 2016 Aug; 33(8):1316-30. PubMed ID: 27342742
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Cost-effectiveness of anti-tumor associated antigen autoantibody screening for hepatocellular carcinoma in the population with chronic hepatitis B-related cirrhosis].
    Zhang M; Li YG; Wang KY; Wang X; Dai LP; Wang P; Ye H; Shi JX; Yang XA; Zhang SX; Zhang JY
    Zhonghua Yi Xue Za Zhi; 2021 Aug; 101(32):2544-2551. PubMed ID: 34407581
    [No Abstract]   [Full Text] [Related]  

  • 74. Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer.
    Lam SW; Wai M; Lau JE; McNamara M; Earl M; Udeh B
    Pharmacotherapy; 2017 Jan; 37(1):94-103. PubMed ID: 27870079
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Evaluation of economic outcomes of "hepatitis B vaccine event reported by media" in China, 2013].
    Zhang SX; Sun PP; Xia Y
    Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Aug; 52(8):837-841. PubMed ID: 30107719
    [No Abstract]   [Full Text] [Related]  

  • 76. Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population.
    Kim KA; Chung W; Choi HY; Ki M; Jang ES; Jeong SH
    Liver Int; 2019 Jan; 39(1):60-69. PubMed ID: 29998565
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors.
    Day FL; Karnon J; Rischin D
    J Clin Oncol; 2011 Aug; 29(24):3270-7. PubMed ID: 21788556
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The First 30 Years of the Universal Hepatitis-B Vaccination-Program in Italy: A Health Strategy with a Relevant and Favorable Economic-Profile.
    Boccalini S; Bonito B; Zanella B; Liedl D; Bonanni P; Bechini A
    Int J Environ Res Public Health; 2022 Dec; 19(23):. PubMed ID: 36498435
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B.
    Kim HL; Kim GA; Park JA; Kang HR; Lee EK; Lim YS
    Gut; 2021 Nov; 70(11):2172-2182. PubMed ID: 33239344
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis.
    Kanwal F; Gralnek IM; Martin P; Dulai GS; Farid M; Spiegel BM
    Ann Intern Med; 2005 May; 142(10):821-31. PubMed ID: 15897532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.